

BEST OF 2023

PROGRAMA
23 FEV 2024

10:30

ABERTURA DO SECRETARIADO

10:50

BOAS-VINDAS

José Carlos Marques

11:00

IMAGIOLOGIA E MEDICINA NUCLEAR

Moderação:

Ana Paula Vasconcelos

Willian Schmitt

Third International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions)

Virchows Archiv (2023) 483:5–20 - <https://doi.org/10.1007/s00428-023-03566-x>

European guidelines for the diagnosis, treatment and follow-up of breast lesions with uncertain malignant potential (B3 lesions) developed jointly by EUSOMA, EUSOBI, ESP (BWG) and ESSO

European Journal of Surgical Oncology (2023) - <https://doi.org/10.1016/j.ejso.2023.107292>

Sofia Santos

Resolution of Nonmass Enhancement Extension to the Nipple at Breast MRI after Neoadjuvant Chemotherapy: Pathologic Response and Feasibility for Nipple-sparing Mastectomy

Radiology Feb 7 2023 <https://doi.org/10.1148/radiol.221777>

João Amorim

DISCUSSÃO

11:45

PATOLOGIA

Moderação:

Fernando Schmitt

Daniel Pinto

Spatial predictors of immunotherapy response in triple-negative breast cancer

Nature, Vol 621 (2023) - <https://doi.org/10.1038/s41586-023-06498-3>

Ricella Silva

Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer

JCO Precis Oncol. 2023 Sep;7:e2300338: doi: 10.1200/PO.23.00338.

Pedro Sequeira

DISCUSSÃO

12:30

CIRURGIA

Moderação:

David Pinto

João Vargas Moniz

Sentinel Lymph Node Biopsy vs No Axillary Surgery in Patients With Small Breast Cancer and Negative Results on Ultrasonography of Axillary Lymph Nodes

The SOUND Randomized Clinical Trial. JAMA 2023. doi: 10.1001/jamaoncol.2023.3759

Rogério Andrès-Luna

Local Recurrence After Breast-Conserving Therapy in Patients With Multiple Ipsilateral Breast Cancer

Results From ACOSOG Z11102 (Alliance). Boughey et al JCO 2023 DOI 10.1200/JCO.22.02553

José Preza Fernandes

DISCUSSÃO

13:15

ALMOÇO

14:30

TERAPÊUTICA SISTÉMICA - DOENÇA PRECOCE

Moderação:

José Luís Passos Coelho

Cláudia Caeiro

Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer

N Engl J Med 2023; 388:1645-1656 - DOI: 10.1056/NEJMoa2212856

Marcio Dabiasi

Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer: Primary results from the phase III NATALEE trial.

2023 ASCO Annual Meeting - DOI: 10.1200/JCO.2023.41.17_suppl.LBA500 Journal of Clinical Oncology 41, no 17_suppl (June 10, 2023) LBA500-LBA500

Catarina Abreu

DISCUSSÃO

15:15

TERAPÊUTICA SISTÉMICA - DOENÇA AVANÇADA

Moderação:

Luís Costa

Sónia Oliveira

Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer

N Engl J Med 2023; 388:2058-2070 - DOI: 10.1056/NEJMoa2214131

Sara Alves

Overall survival with sacituzumab govitecan in hormone receptor- positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial

The Lancet August 23, 2023 - DOI:https://doi.org/10.1016/S0140- 6736(23)01245-X

Alda Tavares

DISCUSSÃO

16:00

COFFEE BREAK

16:15

RADIONCOLOGIA

Moderação:

Helena Pereira

Pedro Meireles

Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer (IMPORT HIGH): a multicentre, phase 3, non-inferiority, open-label, randomised controlled trial.

Lancet 2023; 401: 2124-37; https://doi.org/10.1016/S0140-6736(23)00619-0

Catarina Dias

International multi-disciplinary consensus on the integration of radiation therapy with new systemic treatments for breast cancer: European Society for Radiation Oncology (ESTRO) endorsed recommendations.

TBA

André Laranja

DISCUSSÃO

17:15

ENCERRAMENTO

17:20

ASSEMBLEIA GERAL DA SPS